News & Events CTI Announces Joseph M. McCafferty Promoted to Vice President, Sales North America

CTI Announces Joseph M. McCafferty Promoted to Vice President, Sales North America

June 11, 2014

CTI Clinical Trial and Consulting Services Announces Joseph M. McCafferty Promoted to Vice President, Sales North America

FOR IMMEDIATE RELEASE [Cincinnati, OH ~ June 11, 2014]

CTI Clinical Trial and Consulting Services (CTI) announces Joseph M. McCafferty has been promoted to Vice President, Sales North America, leading the sales team as it continues to grow and expand to geographies across the globe.

McCafferty has been with CTI for nearly a decade, serving as a member of the sales and client management team. Prior to joining CTI, McCafferty spent over 20 years in the pharmaceutical and biotechnology industries, working for companies such as A.H. Robbins Company, Ortho Biotech (Johnson and Johnson), SangStat Medical Corporation, and Wyeth Pharmaceuticals in roles of increasing responsibility.

“Since joining CTI, Joe has provided professionalism in personally managing relationships with more than a dozen pharmaceutical and biotechnology companies,” according to Timothy J. Schroeder, Chief Executive Officer. “His previous leadership roles at companies like Johnson and Johnson and Wyeth Pharmaceuticals will provide the experience necessary to lead the growing CTI North American Business Development Sales team.”

“I look forward to this leadership role where I will mentor and guide the CTI sales team as we continue to expand our activities among more than 80 pharmaceutical and biotechnology companies around the world,” said McCafferty.

 

About CTI Clinical Trial and Consulting Services

CTI Clinical Trial and Consulting Services is an innovative, international drug and device development organization that delivers a full spectrum of clinical trial and consulting services from bench to commercialization with a focus on immunology and a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology and startup firms with clinical and disease area expertise from a unique mix of academic, medical and industry specialists; rich intellectual capital in transplantation, immunology, infectious diseases, hematology, cardiology, nephrology, hepatology, regenerative medicine and rare diseases; flexible study designs that accelerate development programs and deliver high approval ratings that are among the best in the industry; and exceptional global project management and gold standard safety and data management systems that strengthen their program’s success potential. Established in 1999 and headquartered in Cincinnati, OH; CTI has offices in North America, Europe and South America.

 

Original Press Release

Subscribe to our mailing list

* indicates required